EMERALD Pancreas — Department of Oncology
Novartis and MIT collaboration evaluates the use of invisibles in clinical trials
Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer
Oncology Brothers on X: "3. #EMERALD trial for #Elacestrant HR+ mESR1 advanced breast CA -median PFS was 3.8 month - Common AE: musculoskeletal pain, nausea, increased cholesterol #bcsm https://t.co/xCWNyXRObk https://t.co/Jjwpif9xeq https://t.co ...
Resources to support your trial | Emerald Publishing
On trial: Emerald Insight Expert Briefings - Library Matters
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
SABCS 2022: EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer
EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
Gem Enhancement | ExCel Process| Emerald Treatment | Gemstone Emerald Ehancement Treatment | Clarity Enhancement Labs
Laila Agrawal, MD on X: "Results from #EMERALD with oral #SERD elacestrant presented at #SABCS21. Improved PFS from 2.79 to 1.91 mo with greater separation at 6mo and 12mo. I had the
Clinical outcomes of patients within the EMERALD trial of elacestrant... | Download Scientific Diagram
Elacestrant Impresses in EMERALD Trial of Breast Cancer
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
Bertrand Delsuc on X: "$AZN Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial hit on PFS for durva+beva+TACE in HCC (
Case Studies di Emerald - Trial | Sistema Bibliotecario di Ateneo - Università di Pisa
Hagen Kennecke on X: "EMERALD-1: Addition of Durva + Bev but not Durva to TACE improves PFS in large placebo-controlled trial. Other trials of Combo Tx plus TACE awaited. https://t.co/bcVCMD6eU5" / X
EMERALD Study Orkin C. Lancet HIV. 2018 Jan;5(1):e23-e34.
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
Paolo Tarantino on X: "EMERALD trial: significant, albeit modest PFS improvement with elacestrant vs AI/fulvestrant in ET-pretreated MBC patients Good tolerability for elacestrant, with main AE being nausea. Could become the first
The EMERALD Trial Diabetic Substudy. EMERALD Diabetic Analysis To compare myocardial perfusion and infarct sizes in diabetic and non-diabetic patients. - ppt download
Report Back from SABCS 2021: What's the Latest in MBC Research? — Our MBC Life
Breast Cancer Ireland - There is a research study called EMERALD to determine whether an investigational oral endocrine treatment called elacestrant can help people with advanced or metastatic breast cancer. If you
